Rhabdomyosarcoma is a cancer that develops from immature cells capable of forming skeletal muscle. It can arise almost anywhere in the body, including areas where there is little or no skeletal muscle. Common sites include the head and neck, urinary and reproductive organs, arms and legs, abdomen, pelvis, and trunk.
Rhabdomyosarcoma primarily affects children and adolescents, although it can also occur in adults. The main subtypes include embryonal and alveolar rhabdomyosarcoma, along with less common spindle-cell/sclerosing and pleomorphic forms. The tumour's site, molecular features, extent, and response to treatment are important because these influence risk classification and treatment.
Treatment generally combines chemotherapy with surgery, radiation therapy, or both. At Apollo Cancer Centres, care is planned by a multidisciplinary team that may include paediatric or medical oncologists, surgical and radiation oncologists, radiologists, specialist pathologists, head and neck surgeons, urologists, gynaecological oncologists, orthopaedic oncologists, reconstructive surgeons, and rehabilitation specialists.
Risk Factors for Rhabdomyosarcoma
Rhabdomyosarcoma Signs and Symptoms
How Rhabdomyosarcoma Is Diagnosed
Diagnosis begins with a review of symptoms, medical and family history, and a physical examination. The examination is tailored to the tumour's suspected location and may include assessment of the head and neck, limbs, abdomen, pelvis, lymph nodes, or urinary and reproductive systems.
Imaging defines the primary tumour and helps determine whether the cancer has spread. A biopsy is required to confirm rhabdomyosarcoma and identify its histological and molecular features.
Ultrasound
Ultrasound may be used as an initial test for a superficial lump or a tumour suspected in the abdomen, pelvis, testicle, or urinary system.
It can help determine whether a mass is solid or fluid-filled and assess its relationship to nearby structures. Ultrasound may also guide a needle during biopsy.
MRI
MRI is generally the preferred test for defining the local extent of rhabdomyosarcoma. It provides detailed images of the tumour and surrounding muscles, nerves, blood vessels, bones, joints, and organs.
MRI is particularly useful for tumours in the head and neck, pelvis, urinary or reproductive organs, spine, and limbs. The information supports biopsy, surgery, and radiation-treatment planning.
CT Scan
CT may be used to evaluate tumours in the chest, abdomen, pelvis, or other areas where it provides useful anatomical detail.
A CT scan of the chest forms part of staging because rhabdomyosarcoma can spread to the lungs. CT may also be used to guide biopsy of a deep tumour.
PET-CT
PET-CT combines metabolic information with the anatomical detail of CT. It may help evaluate the primary tumour, identify involved lymph nodes, look for distant spread, and assess response to treatment.
Increased tracer uptake is not specific to cancer and can also occur with inflammation or infection. Suspicious findings may require additional imaging or biopsy.
Bone Scan
A bone scan may be used in selected patients to look for cancer involving the skeleton, particularly when PET-CT is unavailable or further assessment is required.
Abnormal activity can also result from fractures, infection, arthritis, or other non-cancerous conditions.
Core Needle Biopsy
Image-guided core needle biopsy is commonly used to diagnose rhabdomyosarcoma. A hollow needle collects several tissue samples, usually under local anaesthesia with sedation or general anaesthesia where appropriate.
The biopsy route should be planned in consultation with the team responsible for definitive surgery so that it does not complicate later treatment.
Incisional Biopsy
An incisional biopsy removes a small portion of the tumour through a surgical incision. It may be required when core biopsy is technically difficult or does not provide sufficient tissue.
The incision should be placed so that the biopsy tract can be removed or incorporated into the definitive local treatment.
Lymph-Node Biopsy
Rhabdomyosarcoma can spread to regional lymph nodes, particularly alveolar tumours arising in an arm or leg and selected tumours in other sites.
Suspicious lymph nodes may be assessed using needle biopsy or surgical sampling. Sentinel lymph-node biopsy may be considered for selected extremity tumours even when nodes are not enlarged on imaging.
Bone-Marrow Examination
Bone-marrow aspiration and biopsy may be recommended for selected patients with metastatic disease, unfavourable tumour features, bone involvement, or other findings that raise concern about marrow spread.
It is not necessarily required for every patient, particularly when modern imaging shows localised disease and the risk of bone-marrow involvement is low.
Laboratory
The biopsy sample may undergo:
Histopathology to confirm rhabdomyosarcoma and identify its morphological subtype
Immunohistochemistry for skeletal-muscle markers such as desmin, myogenin, and MyoD1
Molecular testing for PAX3–FOXO1 or PAX7–FOXO1 gene fusions when alveolar rhabdomyosarcoma is suspected
Molecular testing for selected spindle-cell or sclerosing tumours
Additional testing to distinguish rhabdomyosarcoma from other small round-cell cancers
Specialist paediatric or sarcoma pathology review
Fusion status is particularly important because a tumour with a FOXO1 fusion generally has a different risk profile from a fusion-negative tumour.
Blood tests may include a complete blood count and assessment of kidney, liver, and general health before treatment. There is no blood test or tumour marker that can diagnose rhabdomyosarcoma.
Staging determines how far the cancer has spread and helps guide treatment.
Doctors consider:
Where the tumour began
Its size and involvement of nearby tissues
Whether lymph nodes are affected
Whether it has spread to distant parts of the body
How much tumour remains after biopsy or surgery
The tumour's microscopic and molecular features
Rhabdomyosarcoma may be described as:
Localised: The cancer remains at or near its original site.
Regionally advanced: The cancer involves nearby tissues or lymph nodes.
Metastatic: The cancer has spread to distant parts of the body.
Recurrent: The cancer has returned after treatment.
These findings are combined to classify the cancer as low, intermediate, or high risk. The risk group helps determine the intensity of chemotherapy and whether surgery, radiation therapy, or both are needed.
How Rhabdomyosarcoma Is Treated
Initial Biopsy
For many patients, the first operation is limited to obtaining enough tissue for diagnosis. Attempting to remove the entire tumour before complete imaging and multidisciplinary planning may cause unnecessary functional or cosmetic harm.
The biopsy should be planned so that the pathway can be removed or incorporated into later local treatment.
Wide Local Excision
Complete surgical removal may be performed when the tumour can be removed with an adequate margin without causing unacceptable functional or cosmetic effects.
Surgery may take place at diagnosis or after initial chemotherapy has reduced or controlled the tumour. A pathologist assesses the removed tissue and surgical margins.
Delayed Surgery
Chemotherapy is often given before definitive surgery. This may shrink the tumour or make it easier to remove while preserving nearby organs and function.
Delayed surgery may be considered when it could reduce the amount of radiation required or improve local control without causing excessive morbidity.
Head and Neck Surgery
Tumours of the head and neck may arise near the eye, nose, sinuses, ear, skull base, or throat. Extensive initial surgery can cause major functional or cosmetic effects and is therefore not routinely appropriate for every tumour in these areas.
Treatment often combines biopsy and chemotherapy with carefully planned radiation therapy. Surgery may be considered when complete removal is possible without unacceptable effects or for selected residual or recurrent disease.
Genitourinary Surgery
Rhabdomyosarcoma may affect the bladder, prostate, vagina, cervix, paratesticular tissues, or other parts of the urinary and reproductive systems.
Treatment aims to control the cancer while preserving urinary, bowel, sexual, reproductive, and hormonal function where possible. The procedure may range from biopsy or limited excision to more extensive surgery, depending on the tumour's site and response to treatment.
Regional lymph-node assessment may be required for selected paratesticular tumours, particularly in older children and adolescents.
Limb-Sparing Surgery
Most tumours in an arm or leg can be treated without amputation. Surgery aims to remove the cancer while preserving useful muscle, nerve, blood-vessel, bone, and joint function.
Regional lymph nodes require careful assessment because extremity rhabdomyosarcoma has a recognised risk of lymphatic spread.
Recurrent Tumour Surgery
Surgery may be considered when rhabdomyosarcoma returns at the original site or in a limited distant location.
The decision depends on whether complete removal is feasible, previous surgery and radiation, disease-free interval, extent of recurrence, and expected effect on function.
Metastasis Surgery
Surgical removal of a limited metastatic lesion may be considered in selected cases as part of a wider treatment plan.
Chemotherapy remains essential, and surgery is not appropriate when disease is too widespread to remove safely or when another local treatment would be more suitable.
Chemotherapy
Chemotherapy is an essential component of treatment for almost every patient with rhabdomyosarcoma. It treats the primary tumour and cancer cells that may have spread but are too small to be detected on scans.
A commonly used combination includes vincristine, dactinomycin, and cyclophosphamide, often abbreviated as VAC. Other protocols may use ifosfamide, vincristine, and dactinomycin or incorporate additional medicines according to the patient's risk group and treatment protocol.
Chemotherapy may be given:
Before definitive surgery or radiation therapy
During the period of local treatment
After surgery or radiation to complete systemic treatment
For recurrent or metastatic disease
The selection, dose, and duration of treatment depend on the risk group, age, tumour site, molecular findings, organ function, and protocol being followed.
Supportive care may include infection prevention and treatment, anti-sickness medicines, blood-product support, nutrition care, pain management, and medicines to support blood-cell recovery.
Recurrent Disease Treatment
When rhabdomyosarcoma returns, systemic treatment is selected according to the medicines previously received, the time since treatment, the site of recurrence, and the patient's overall health.
Treatment may include different chemotherapy combinations, surgery, radiation therapy, targeted treatment for a relevant alteration, or participation in a clinical trial.
Targeted Therapy
Targeted therapies are not part of standard initial treatment for most rhabdomyosarcomas. Medicines acting on specific growth pathways are being studied for recurrent or treatment-resistant disease.
Molecular findings may occasionally identify a treatment option, particularly in some spindle-cell or sclerosing tumours. Availability and evidence vary, and treatment should be considered by a specialist molecular tumour board or within a clinical trial where appropriate.
Immunotherapy
Immunotherapy does not currently have an established routine role in rhabdomyosarcoma because responses to available immune-checkpoint inhibitors have generally been limited.
It may be considered in exceptional cases with an appropriate biomarker or as part of a clinical trial.
Precision Oncology
Molecular testing helps classify rhabdomyosarcoma and refine risk assessment. Identifying a FOXO1 fusion is particularly important when alveolar morphology is suspected.
Testing may also identify alterations associated with spindle-cell or sclerosing rhabdomyosarcoma and distinguish the tumour from other cancers that appear similar under the microscope.
Broader molecular profiling may be considered in recurrent or advanced disease when it could support targeted therapy or clinical-trial eligibility. It is not necessarily required for every newly diagnosed patient.
Proton Therapy
Proton therapy may be considered when treatment planning shows that it can meaningfully reduce radiation exposure to nearby healthy tissues compared with advanced photon therapy.
This may be particularly relevant for children, whose developing organs and tissues can be sensitive to radiation, and for tumours near the brain, eyes, skull base, spinal cord, heart, lungs, bowel, bladder, or reproductive organs.
For appropriate patients, Apollo Proton Cancer Centre can compare proton and advanced photon-radiation plans. Proton therapy is not required for every patient and does not replace the need for chemotherapy or appropriate surgery.
External Beam Radiation Therapy
Radiation therapy is an important part of local treatment for many patients with rhabdomyosarcoma. It may be used when visible tumour remains after biopsy or surgery, when surgical margins contain cancer cells, when lymph nodes are involved, or when surgery would cause unacceptable functional or cosmetic effects.
The treatment volume and dose depend on the original tumour extent, site, clinical group, response to chemotherapy, patient's age, surgical findings, and molecular risk factors.
Radiation may occasionally be omitted or reduced in carefully selected low-risk patients whose tumours have been completely removed. This decision depends on the protocol and should not be generalised to all patients.
Intensity-Modulated Radiation Therapy
IMRT adjusts the intensity of individual radiation beams to conform the dose more closely to the tumour.
It is particularly useful for tumours near the brain, spinal cord, eyes, salivary glands, bowel, bladder, kidneys, reproductive organs, growth plates, or other sensitive structures. Image guidance is generally used to improve treatment accuracy.
Brachytherapy
Brachytherapy places a radiation source within or close to the area requiring treatment. It may be considered for selected tumours in the vagina, bladder, prostate, head and neck, or another suitable site.
This approach can deliver a concentrated dose while limiting exposure to surrounding tissues. Suitability depends on the tumour's location, size, response to chemotherapy, and available specialist expertise.
Stereotactic Radiation Therapy
Stereotactic body radiation therapy delivers highly focused radiation over a limited number of sessions. It may be considered for selected metastatic or recurrent lesions when surgery is not feasible.
Its use depends on the lesion's size, location, proximity to critical structures, previous radiation exposure, and the overall extent of disease.
Soft-Tissue Reconstruction
Removing a large tumour may leave a defect involving skin, fat, or muscle. Reconstructive surgeons may transfer healthy tissue from another area to cover the wound, protect exposed structures, and restore contour.
Local or free flaps may be used depending on the site and extent of surgery.
Functional Reconstruction
Surgery involving the face, jaw, throat, bladder, reproductive organs, or limbs may affect speech, swallowing, appearance, movement, continence, or other functions.
Reconstructive procedures are planned according to the tissues removed, the patient's age, remaining growth, and the expected effect of radiation therapy.
Nerve and Vessel Reconstruction
When a tumour directly involves an important nerve or blood vessel, specialist surgeons may be required to remove and reconstruct the affected structure.
Recovery varies and may require prolonged physiotherapy, splinting, pain management, or functional adaptation.
Pelvic Reconstruction
Surgery for selected bladder, prostate, vaginal, cervical, or pelvic tumours may require reconstruction of the urinary tract, pelvic floor, vaginal tissues, or bowel.
The aim is to preserve function where oncologically safe and support the patient's long-term development and quality of life.
The outlook for rhabdomyosarcoma varies considerably. Many children with localised, lower-risk disease can be treated successfully, while metastatic, recurrent, or molecularly higher-risk disease is more difficult to treat,
Regular follow-up is important because recurrence may occur near the original tumour or elsewhere, particularly in the lungs, bones, bone marrow, or lymph nodes.
Long-term follow-up also monitors growth, development, organ function, fertility, learning, hearing where relevant, and the functional effects of surgery or radiation therapy.
Why Choose ACC for Rhabdomyosarcoma Treatment